secwatch.observer — SEC 8-K summary
======================================

Issuer:     Exousia Bio, Inc. (LMMY)
CIK:        0001939937
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001683168-25-008486
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 5.01, 2.01, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LAMY acquires Exousia Ai in reverse merger; appoints Matthew Dwyer as sole officer and director
--------------------------------------------------------------------------------

- Closed acquisition of Exousia Ai, issuing 62,223,000 shares of common stock to Exousia Ai shareholders.
- Zhang Shengwu resigned as sole officer/director; Matthew Dwyer appointed as replacement effective November 17, 2025.
- Exousia Ai is a clinical-stage biotech developing plant-based exosome therapies, initially for oncology.
- Exousia Ai received FDA Orphan Drug Designation in November 2025 for its exosome-based glioblastoma multiforme (GBM) treatment.
- The Company adopts Exousia Ai's business plan and expects to use its proprietary exosome loading technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1939937/000168316825008486/0001683168-25-008486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1939937/000168316825008486/lamy_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-008486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer